Fig. 2

Predicted direct and medical costs and health status (EQ-5D-5L) for mild versus moderate or severe haemophilia. *P < 0.01, **P < 0.001 vs mild disease. Cost models adjusted for haemophilia severity (base outcome: mild), age, BMI, country ( base outcome: Germany), comorbidities (base outcome: 0 comorbidities) and weight-adjusted factor consumption; health status model also adjusted for education level (base outcome: primary). Direct medical and societal costs are captured at patient level for a period of 12 months